Pazopanib/Encorafenib Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Encorafenib may change how pazopanib is processed in your body. Also, both medicines may affect your heart rhythm.
What might happen:
The amount of your pazopanib in your body may change. If you have too much pazopanib in your body, you may have more side effects than expected, including an irregular heart rhythm, which may be life-threatening. If you have too little pazopanib in your body, it may not work as well.
What you should do about this interaction:
Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want to change your medicines or perform an electrocardiogram (ECG) to check your heart rate and rhythm. Let your doctor know right away if you notice an irregular heartbeat or have any dizziness or fainting episodes.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Braftovi (encorafenib) capsules US prescribing information. Array BioPharma October, 2023.
- 2.Votrient (pazopanib) US prescribing information. GlaxoSmithKline August, 2020.
- 3.Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010 Mar 2;55(9):934-47.
- 4.Abu Rmilah AA, Lin G, Begna KH, Friedman PA, Herrmann J. Risk of QTc Prolongation Among Cancer Patients Treated with Tyrosine Kinase Inhibitors. Int J Cancer. 2020 May 25.
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.